07:00 , Oct 17, 2011 |  BC Week In Review  |  Company News

Novagali, Santen Pharmaceuticals Co. Ltd. deal

Santen acquired a 50.55% stake in Novagali for €6.15 per share through the purchase of 8.2 million shares for a total of €50.7 million ($68.6 million) from a group of shareholders that includes funds managed...
07:00 , Oct 3, 2011 |  BC Week In Review  |  Company News

Novagali, Santen deal

Santen will acquire fellow ophthalmic company Novagali for €6.15 per share, or about €100 million ($134.2 million). The price is a 71% premium to Novagali's close of €3.59 on Sept. 27, before the deal was...
00:14 , Sep 29, 2011 |  BC Extra  |  Company News

Santen to acquire Novagali

Santen Pharmaceutical Co. Ltd. (Tokyo:4536; Osaka:4536) will acquire fellow ophthalmic company Novagali Pharma S.A. (Euronext:NOVA) for EUR 6.15 per share, or about EUR 100 million ($134.2 million). The price is a 71% premium to Novagali's...
08:00 , Nov 8, 2010 |  BioCentury  |  Finance

Zeal for Zealand

Two weeks after Europe's largest biotech underwriter, Piper Jaffray, decided to stop selling securities in the region, Zealand Pharma A/S has proposed what would be the largest biotech IPO in Europe this year and the...
07:00 , Jun 14, 2010 |  BC Week In Review  |  Financial News

Cytheris completes venture financing

Cytheris S.A. , Paris, France   Business: Infectious, Cancer   Date completed: 6/7/10   Type: Venture financing   Raised: E12 million ($14.3 million)   Investors: CDC Entreprises; Bioam Gestion; Caisse de Depot et Placement du...
07:00 , Sep 21, 2009 |  BC Week In Review  |  Financial News

FAB Pharma completes venture financing

FAB Pharma S.A.S. , Paris, France   Business: Infectious   Date completed: 9/14/09   Type: Venture financing   Raised: €2.3 million ($3.3 million)   Investors: CDC Innovation; Bioam Gestion  ...
07:00 , Sep 14, 2009 |  BioCentury  |  Emerging Company Profile

Narrower is Better: Sidebar: Corporate Profile

FAB Pharma S.A.S. Paris, France Technology: Compounds against fatty acid biosynthesis I (FAB I) Disease focus: Infectious Clinical status: Phase I Founded: 2009 by CDC Innovation and Bioam Gestion University collaborators: None Corporate partners: None...
07:00 , Sep 14, 2009 |  BioCentury  |  Emerging Company Profile

FAB Pharma: Narrower is Better

FAB Pharma S.A.S. believes that by targeting a new mechanism of action in the fatty acid biosynthesis pathway, it can develop narrow-spectrum antibiotics against methicillin-resistant Staphylococcus aureus with a much better side effect profile than...
02:32 , Mar 6, 2008 |  BC Extra  |  Financial News

TxCell raises EUR 10.5 million

TxCell (Sophia Antipolis, France) raised EUR 10.5 million ($15.9 million) in a series B round led by existing investor Auriga Partners. Other existing investors AXA Private Equity; Bioam Gestion; CDC Innovation; and Seventure also participated....
07:00 , Apr 19, 2004 |  BioCentury  |  Emerging Company Profile

Corporate Profile

Targacept Inc. Winston-Salem, N.C. Technology: Neuronal nicotinic receptor (NNR) chemistry and biology Disease focus: Neurology Clinical status: Phase II Founded: 2000 as a spinout from R.J. Reynolds Tobacco Co. University collaborators: Wake Forest University School...